naveglitazar
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 21, 2003 (NCT00065312)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
PPARA agonist
Development stopped (PMID:20932114). There are reports of adverse events associated with PPARalfa/gamma dual agonist, for example weight gain, increased risk of bladder cancer and hyperplasia.
PPARG agonist
Development stopped (PMID:20932114). There are reports of adverse events associated with PPARalfa/gamma dual agonist, for example weight gain, increased risk of bladder cancer and hyperplasia.
Chemistry & pharmacology
Loading structure…
SMILES
CO[C@@H](Cc1ccc(OCCCOc2ccc(Oc3ccccc3)cc2)cc1)C(=O)O- Mol. weight
- 422.48 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL181954 ↗
Also known as
- alpha-methoxy-4-(3-(4-phenoxyphenoxy)propoxy)benzenepropionic acid
- ly519818
- ly 519818
- ly-519818
- ly-519818
- ly-519818
- ly-9818
- ly-9818
- naveglitazar
- naveglitazar
- naveglitazar
- naveglitazar
- naveglitazar
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00065312 | Phase 2 | Jul 21, 2003 | Eli Lilly |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 1 | 1 | 1 | 2003 |
1 organizations
Page 1 / 1